Morgan Stanley upgraded Alteryx to Overweight from Equal Weight with an unchanged price target of $54. With the shares down nearly 30% year-to-date, Alteryx’s valuation undervalues the company’s growth and profit potential in the years ahead, the analyst tells investors in a research note. The company is nearing $1B in annual recurring revenue with 48% penetration of the G2K and set to deliver improving profitability and free cash flow, says the firm. It sees Alteryx playing a central role in streamlining the analytics process for the large enterprise market.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AYX:
- Alteryx price target raised to $42 from $35 at Needham
- Is Alteryx (NYSE:AYX) Up for Sale?
- Alteryx could be valued near $44 in potential sale, says Truist
- Alteryx jumps after Reuters says company exploring possible sale
- Alteryx up 11% after Reuters says company exploring sale
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue